Market Overview

The Key Level In Gilead Sciences You Need To Watch For

Share:
Related GILD
Gilead Looking To Buy Incyte? It Makes Sense
Wall Street's M&A Chatter From March 10-12
Marketplace Roundtable: Biotech Hanging In The Balance (Seeking Alpha)

Gilead Sciences, Inc. (NASDAQ: GILD) is scheduled to report its fourth-quarter 2014 financial results on Thursday. Analysts expect the company to deliver earnings of $2.22 per share for the quarter, and $7.92 per share for the whole year. Fourth-quarter revenues are expected to come in at $6.72 billion, up about 115 percent year-over-year, while full-year revenues are projected at $24.3 billion.

Related Link: Gilead Could Miss Earnings (Hint: Watch Drug Sales)

CMT Christian Tharp told Benzinga in an email that, “Over the last 5 months GILD has stalled at its $110 resistance on 3 separate occasions. The one time the stock pushed above that mark it led to a high of almost $117/share. Watch for GILD to possibly break that $110 mark on a well received earnings report. Otherwise, $100 is the key level to monitor on the downside.”

Heading into earnings, analysts are primarily bullish on Gilead. Four firms, including JP Morgan, Deutsche Bank, Morgan Stanley and Barclays have maintained or initiated Outperform ratings on the stock in the past two months.

Shares Of Gilead traded recently at $105.22, down 0.9 percent.

Latest Ratings for GILD

DateFirmActionFromTo
Mar 2017UBSDowngradesBuyNeutral
Feb 2017CitigroupDowngradesBuyNeutral
Nov 2016Stifel NicolausInitiates Coverage OnBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Christian Tharp MarketfyAnalyst Color Previews Exclusives Analyst Ratings Trading Ideas

 

Related Articles (GILD)

View Comments and Join the Discussion!